These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

63 related articles for article (PubMed ID: 8759404)

  • 1. [Androgen excess in women and the metabolic syndrome (syndrome X)].
    Cabrijan T; Lipovac M; Misjak M
    Lijec Vjesn; 1996 Mar; 118 Suppl 1():24-7. PubMed ID: 8759404
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Detecting insulin resistance in polycystic ovary syndrome: purposes and pitfalls.
    Legro RS; Castracane VD; Kauffman RP
    Obstet Gynecol Surv; 2004 Feb; 59(2):141-54. PubMed ID: 14752302
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of androgens on insulin action in women: is androgen excess a component of female metabolic syndrome?
    Corbould A
    Diabetes Metab Res Rev; 2008 Oct; 24(7):520-32. PubMed ID: 18615851
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Early metabolic abnormalities--insulin resistance, hyperinsulinemia, impaired glucose tolerance and diabetes, in adolescent girls with polycystic ovarian syndrome].
    Otto-Buczkowska E; Jarosz-Chobot P; Deja G
    Przegl Lek; 2006; 63(4):234-8. PubMed ID: 17080748
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolic characteristics of women with polycystic ovaries and oligo-amenorrhoea but normal androgen levels: implications for the management of polycystic ovary syndrome.
    Barber TM; Wass JA; McCarthy MI; Franks S
    Clin Endocrinol (Oxf); 2007 Apr; 66(4):513-7. PubMed ID: 17371468
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical and biochemical characterization of women with polycystic ovary syndrome in North Rhine-Westphalia.
    Hahn S; Tan S; Elsenbruch S; Quadbeck B; Herrmann BL; Mann K; Janssen OE
    Horm Metab Res; 2005 Jul; 37(7):438-44. PubMed ID: 16034717
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association between the polycystic ovary syndrome and the metabolic syndrome in Puerto Rico.
    Rabelo Acevedo M; Vick MR
    P R Health Sci J; 2005 Sep; 24(3):203-6. PubMed ID: 16329683
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The evaluation of metabolic parameters and insulin sensitivity for a more robust diagnosis of the polycystic ovary syndrome.
    Amato MC; Galluzzo A; Finocchiaro S; Criscimanna A; Giordano C
    Clin Endocrinol (Oxf); 2008 Jul; 69(1):52-60. PubMed ID: 18034780
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical and biochemical characteristics of polycystic ovary syndrome in Korean women.
    Chae SJ; Kim JJ; Choi YM; Hwang KR; Jee BC; Ku SY; Suh CS; Kim SH; Kim JG; Moon SY
    Hum Reprod; 2008 Aug; 23(8):1924-31. PubMed ID: 18579512
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Insulin resistance in polycystic ovary syndrome.
    Prelevic GM
    Curr Opin Obstet Gynecol; 1997 Jun; 9(3):193-201. PubMed ID: 9263704
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of pharmaceutical intervention on lipid profile in polycystic ovary syndrome.
    Diamanti-Kandarakis E; Kandaraki E; Christakou C; Panidis D
    Obes Rev; 2009 Jul; 10(4):431-41. PubMed ID: 19413702
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiometabolic abnormalities in the polycystic ovary syndrome: pharmacotherapeutic insights.
    Westerveld HE; Hoogendoorn M; de Jong AW; Goverde AJ; Fauser BC; Dallinga-Thie GM
    Pharmacol Ther; 2008 Sep; 119(3):223-41. PubMed ID: 18602948
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma metastin levels are negatively correlated with insulin resistance and free androgens in women with polycystic ovary syndrome.
    Panidis D; Rousso D; Koliakos G; Kourtis A; Katsikis I; Farmakiotis D; Votsi E; Diamanti-Kandarakis E
    Fertil Steril; 2006 Jun; 85(6):1778-83. PubMed ID: 16650418
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of insulin sensitizers in polycystic ovarian syndrome.
    Baillargeon JP
    Curr Opin Investig Drugs; 2005 Oct; 6(10):1012-22. PubMed ID: 16259222
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Polycystic ovary syndrome in men: Stein-Leventhal syndrome revisited.
    Kurzrock R; Cohen PR
    Med Hypotheses; 2007; 68(3):480-3. PubMed ID: 17134841
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Insulin resistance, the insulin resistance syndrome, and cardiovascular disease.
    Reaven GM
    Panminerva Med; 2005 Dec; 47(4):201-10. PubMed ID: 16489319
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Polycystic ovarian syndrome: the commonest cause of hyperandrogenemia in women as a risk factor for metabolic syndrome.
    Diamanti-Kandarakis E; Christakou C; Kandarakis H
    Minerva Endocrinol; 2007 Mar; 32(1):35-47. PubMed ID: 17353865
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Polycystic ovary syndrome.
    Shelley DR; Dunaif A
    Compr Ther; 1990 Nov; 16(11):26-34. PubMed ID: 2269012
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Exploration of the classification of polycystic ovarian syndrome].
    Lin JF; Li X; Zhu MW
    Zhonghua Fu Chan Ke Za Zhi; 2006 Oct; 41(10):684-8. PubMed ID: 17199924
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Androgen circle of polycystic ovary syndrome.
    Homburg R
    Hum Reprod; 2009 Jul; 24(7):1548-55. PubMed ID: 19279033
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.